M.B.B.S (Honours II Division I), University of NSW1978
F.R.A.C.S. Part I 1980, F.R.A.C.S. (Urology) Part 2 1988
Professor Stricker was awarded Australia’s 2nd highest award, the Officer of the Order of Australia (AO) on the Australia Day 2015 Honours list for “ Distinguished service to medicine and medical research, as a leading urologist, a robotic surgery pioneer, a teacher and mentor, and as an advocate for prostate cancer awareness “.
Selected Current Appointments
- Chair Department of Urology, St Vincent's Private Hospital and Clinic 2003 to date.
- Director of the St Vincent's Prostate Cancer Centre 2004 to date.
- Clinical Director of Prostate Cancer at The Kinghorn Cancer Centre 2013 to date.
- Clinical Associate Professor UNSW Medical School 2003 to date
- Clinical Associate Professor Sydney Medical School, University of Sydney 2013 to date
- Clinical Professor, School of Health Sciences, University of Tasmania, 2013 to date
- Clinical Director - Australian Prostate Cancer Research Centre – NSW node 2013 to date
- Conjoint Professor, School of Medicine, University of Western Sydney
Professor Phillip Stricker is an Urologist and one of the leading experts in the treatment of prostate cancer in Australia. He is Chairman of the Department of Urology at St Vincent’s Campus, the Director of the St Vincent’s Prostate Cancer Centre, Clinical Director of the Australian Prostate Cancer Research Centre – NSW and was an inaugural Director of the Prostate Cancer Foundation of Australia. He was the first person in Australia to specialise exclusively in the care of men with prostate cancer. In February 2006 he commenced the first robotic program in NSW at St Vincent's Hospital. Since then he has performed over 2000 robotic prostate cancer cases,being the most in NSW and being only one of three robotic surgeons to achieve that in Australasia. He continues to perform open surgery and currently has performed in excess of 4500 open prostate cancer surgery cases being the most in Australasia. In non-surgical treatments he was one of the first to use low dose rate and high dose rate brachytherapy in Australasia and has now performed over 1,000 high dose rate and over 1000 low dose rate brachytherapies. He was one of the first to use active surveillance with one of the largest cohorts in the world ( >1000 patients).
Professor Stricker also has a long clinical and research track record of treating Benign Prostatic Hypertrophy including all the medications, laser surgery (being the first to perform greenlight laser in Australia), urolift treatment and TURP.
His area of research currently focuses on the quality of life in patients after treatments ,improving surgical techniques , new techniques in robotic prostate surgery , introducing new treatments that are less invasive and with less side effects and investigating multiparametric magnetic resonance imagining alone and with combidex as an aid to biopsy, as a diagnostic tool and to assess the extent and aggressiveness of prostate cancer and to guide therapies . The use of Prostate Specific Membrane Antigen (PSMA) PET scans for the detection and evaluation of prostate cancer is a new research area of interest for Prof Stricker. In 2013, he was appointed the Clinical Director of the Australian Prostate Cancer Research Centre – NSW, which is funded by the Australian Federal Government. This Centre coordinates prostate cancer research across the St Vincent's Campus, Garvan Institute of Medical Research/The Kinghorn Cancer Centre, Royal Prince Alfred Hospital/The Chris O’Brien Lifehouse and Royal North Shore Hospital. It is also in collaboration with researchers in Victoria, Queensland, South Australia and Western Australia. His international collaborative partnerships include the Memorial Sloan-Kettering Centre, New York, Cornell University, New York, Case Western Reserve University, Ohio, the Robotic Institute, Florida, Beth Israel Medical Center, New York and the University College Hospital, London. Together with the Garvan Institute of Medical Research, he has established a prostate cancer repository, which has collected clinical data and prostate cancer tissues samples for over 13,000 men one of the largest in the world. This has become a valuable resource for researchers who not only want to discover the molecular causes of prostate cancer but also the outcomes of diagnosis, treatment and prevention.
Translation - Current selected Achievements
Greater than 1000 cases on active surveillance since 1992. The largest series in Australia. Structured program of follow-up with PSA, transperineal biopsies of the prostate and MRI scans.
Open and Robotic Radical Prostatectomy:
Achieved international standard outcomes with <10% positive margins, up to 92% potency recovery and <2% long-term incontinence. These results have been presented and published in state, national and international meetings and journals.
First described this technique in 1995, published and presented extensively on it’s accuracy, safety and technique, has performed over 7,000 cases,and recently wrote the chapter by invitation in Hinman’s Textbook of Urology
MRI & PET Scanning
one of the pioneers of MRI prostate cancer imaging and PSMA Pet Scanning and has extensively presented and published on it’s role in detection, targeted biopsy ( including MR/US Fusion techniques), staging and monitoring and planning therapy.
One of the pioneers of focal therapy using IRE ( Nanoknife ) . He currently has the largest world experience and is involved in trials evaluating it’s safety, effectiveness and ideal patient selection . He has presented and published extensively nationally and internationally.
Current Major Grants
- 2010 – 2014
NHMRC Enabling Grant (ID No. 614296). 'Australian Prostate Cancer Collaboration (APCC) Bio-Resource'. Clements J, Sutherland RL, Tilley W, Risbridger G, Marshall V, Roder D, Stahl J, Gardiner F, Nicol D, Frydenberg M, Pedersen J, Stricker P . $2,000,000.00
- 2010 – 2015
Cancer Institute NSW. 21 Program Grant.
- 2013 – 2017
Federal Government Grant – 'The Chronic Disease Prevention and Service Improvement'. Australian Prostate Cancer Research Centre NSW. $5.5million.
- 2016 – 2017
NHMRC Project Grant - “Epigentic Changes in the Prostate Cancer Environment”. Clark S, Horvath L, Kench J, Stricker P et al. $848,954
- 2016 – 2017
Paul Ramsay Foundation - “Magnifi Trial”. Van Leeuwen P and Stricker P. $759,000
- 2016 – 2017
Paul Ramsay Foundation - “LuPSMA Trial”. Emmett L and Stricker P. $400,000
- Over 100 peer-reviewed publications
- Top 9 Publications
- Bianco-Miotto T , Chiam K , et al Stricker PD , et al. Global levels of specific histone modifications and an epigenetic gene signature predict prostate cancer progression and development. Cancer Epidemiol Biomarkers Prev. 2010 Oct;19 (10):2611-22. ( This study established the importance of histone modifications in predicting prostate cancer relapse and has identified an epigenetic gene signature associated with prostate tumorigenesis.)
- King MT , Viney R , Smith DP , et al., Stricker PD Survival gains needed to offset persistent adverse treatment effects in localised prostate cancer. Br J Cancer. 2012 Feb 14;106(4):638-45. ( Considerable variation in trade-offs among individuals underlines the need to inform patients of long-term consequences and incorporate patient preferences into treatment decisions).
- Moore BM, Savdie R, Pebenito RA, Haynes AM, Matthews J, Delprado W, Rasiah KK, Stricker PD . The impact of nerve sparing surgery (NSS) on incidence and location of positive surgical margins in radical prostatectomy. BJU Int. 2012 Feb; 109(4): 533-8.
(With appropriate selection of patients, NSS does not increase the risk of positive surgical margins, whether the cancer is organ confined or extracapsular extension is present. The adverse impact of the NSS procedure in the hands of an experienced surgeon is minimal and is a realistic compromise to obtain the increase in health-related quality of life offered by NSS).
- Thompson J, Egger S, Bohn M, Haynes A-M, Matthews J, Rasiah K and Stricker P . Superior quality of life and improved surgical margins are achievable with robotic radical prostatectomy after a long learning curve: a prospective single-surgeon study of 1552 consecutive cases. Eur Urol 2014, 64 (521-531). ( The robot-assisted radical prostatectomy (RARP) learning curve extends beyond 700 cases. The trifecta of superior urinary, sexual, and oncologic outcomes requires 300 RARPs. High-risk cancers should be avoided early in the learning curve. Learning RARP may not improve outcomes for late-career or low-volume surgeons).
- Thompson JE, van Leeuwen PJ, Moses D, Shnier R, Brenner P, Delprado W, Pulbrook M, Bohm M, Haynes AM, Hayen A Stricker PD . The Diagnostic Performance of Multiparametric Magnetic Resonance Imaging to Detect Significant Prostate Cancer . J . Urol . 2015 Oct 31 . pii:S0022-5347(15)05163-0. Doi : 10.1016/j.uro.2015.10.140 ( Multiparametric magnetic resonance imaging reported by expert radiologists achieved an excellent negative predictive value and a moderate positive predictive value for significant prostate cancer at 1.5 and 3.0 Tesla. This could reduce unnecessary biopsies and act as a secondary screening tool and avoid overdetection ).
- Tran M, Thompson J, Savdie R, Moses M, Schnier R, Brenner P, Delprado W, Boehm M, Haynes AM, Pulbrook M and Stricker PD. Combination of multi-parametric magnetic resonance imaging and transperineal template-guided mapping biopsy of the prostate to identify candidates for hemi-ablative focal therapy. BJU International February 2015:DOI: 10.1111/bju.13090
- Morigi JJ, Stricker S, van Leeuwen P, Tang R, Ho B, Nguyen Q, Hruby G, Fogarty G, Jagavkar R, Kneebone A, Hickey A, Fanti S, Tarlinton L and Louise Emmett L . Prospective Comparison of the detection rate of18F-Fluoromethylcholine and 68Ga-PSMA-HBED PET/CT in men with prostate cancer with rising PSA post curative treatment, being considered for targeted therapy. J Nucl Med Published June 25, 2015 as doi:10.2967/jnumed.115.160382
- Thompson JE, van Leeuwen PJ, Moses D, Shnier R, Brenner P, Delprado W, Pulbrook M, Bohm M, Haynes AM, Hayen A and Stricker PD . The diagnostic performance of multiparametric magnetic resonance imaging to detect significant prostate cancer. J Urology 2016 May 195: 1428-1435.
- van Leeuwen PJ, Emmett L, Ho B, Delprado W, Ting F, Nguyen Q and Stricker PD. Prospective evaluation of 68Gallium-prostate-specific membrane antigen positron emission tomography/computed tomography for preoperative lymph node staging in prostate cancer. BJU international. 2017;119:209-15 doi: 10.1111/bju.13540. Epub 2016 Jun 18
Top 5 Recent Invited Conference Presentations
- Stricker PD. The role of focal therapy in localized prostate cancer, preliminary Australian results. Invited speaker. American Urological Association Annual Meeting 15-19 May 2015, New Orleans, Louisiana, USA
- Stricker PD. MRI nomogram for prostate cancer. Invited speaker. 16 th Asia-Pacific Prostate Cancer Conference. Cairns Australia 2016
- Stricker PD. Nanoknife focal therapy. Invited speaker. 3 rd Friends of Israel Urological Symposium 5-7 th July 2016. Tel-Aviv, Israel.
- Siriwardana A, Thompson J, Doig S, Kalsbeek A, Emmett L, Delprado W, Wong D, Samaratunga H, Haynes A, Couglin G and Stricker PD. Robot-assisted Salvage Node Dissection For Oligometastatic Nodal Disease Detected By 68Gallium-PSMA PET/CT: A Multicentre Retrospective Series. USANZ 2017 Annual Scientific Meeting 24-27 th February 2017, Canberra, Australia 2017 Keith Kirkland Prize Awarded
- Stricker PD. My learning curve and improving patient’s erectile function recovery. Invited speaker. Sydney Robotic Summit: Research and Innovation. 24 th June 2017 Sydney Australia.
Other track record achievements in the past 5 years
- Supervision and mentoring of eight research fellows to Masters or PhD including The Rob Sutherland Fellow
- Production of patient oriented DVDs for prostate cancer care
- Invited speaker to twenty national and international conferences and meetings
- Member of The Expert Advisory Panel to develop books on 1.Treatment of Localised Prostate Cancer –both editions (NHMRC approved )2. Treatment of Advanced Prostate Cancer ( NHMRC Approved ) 3. Clinical Practice guidelines for PSA Testing (PCFA & NHMRC approved )
- Supervisor of Robotic Surgical Training for Registrars, Fellows and Consultants
- Reviewer of Publications for multiple Journals including European Urology, Journal of Urology, Medical Journal of Australia.